Award of NHS Midlands and East Branded Medicines Framework (Tranche B & Annual Tranche)

About

NHS England awarded a contract to Sandoz Ltd, Teva UK Limited, Roche Products Ltd, Kent Pharma Ltd, UL Global Pharma, Celltrion Healthcare United Kingdom Limited, Merck Sharpe & Dohme (UK) Limited, Amgen Ltd, Mylan, Thornton and Ross Ltd, and Janssen for the NHS Framework for Midlands and East Branded Medicines – Tranche B and Annual Tranche.

The framework covers the supply of branded medicines under two lots: Tranche B (reference CM/PHR/20/5608/01) with a period from 1 March 2023 to 28 February 2025 and an option to extend for up to 24 months at the Authority's discretion; and Annual Tranche (reference CM/PHR/20/5608/02) with a period from 1 March 2023 to 29 February 2024 and an option to extend for up to 12 months at the Authority's discretion.

The total contract value is £480,429,000.